CAJ | 학술논문

目的评价卡培他滨在转移性鼻咽癌维持治疗的近期疗效和毒性反应.方法将我院收治63例转移性鼻咽癌患者在一线姑息化疗4~6个疗程获得CR、PR、SD后随机分为单药卡培他滨维持治疗组和观察组,对比分析两组患者的近期疗效和毒性反应.结果治疗组患者临床疗效明显优于观察组(P<0.05),治疗组患者治疗后2年生存率优于观察组(P<0.05),治疗组患者不良反应较对照组高,但患者能耐受.结论卡培他滨在转移性鼻咽癌维持治疗中疗效佳,不良反应可耐受,值得临床进一步研究.
목적평개잡배타빈재전이성비인암유지치료적근기료효화독성반응.방법장아원수치63례전이성비인암환자재일선고식화료4~6개료정획득CR、PR、SD후수궤분위단약잡배타빈유지치료조화관찰조,대비분석량조환자적근기료효화독성반응.결과치료조환자림상료효명현우우관찰조(P<0.05),치료조환자치료후2년생존솔우우관찰조(P<0.05),치료조환자불량반응교대조조고,단환자능내수.결론잡배타빈재전이성비인암유지치료중료효가,불량반응가내수,치득림상진일보연구.
@@@@Objective To evaluate capecitabine in the maintenance treatment of metastatic nasopharyngeal effcacy and toxicity. Method In our hospital, 63 patients with metastatic nasopharyngeal carcinoma patients in the frst-line palliative chemotherapy 4-6 cycle with who get CR, PR, SD, were randomly divided into single-agent capecitabine maintain the treatment group and the observation group, analysis of the effcacy and toxicity of the two groups of patients. Results The clinical effcacy of the treatment group was signifcantly better than the observation group(P<0.05), 2-year survival rate of treated patients after treatment is better than the observation group(P<0.05). Adverse reactions in patients of the treatment group compared with the control group, but the patient can tolerate. Conclusion Capecitabine in the metastatic nasopharyngeal maintaining good effcacy in the treatment, adverse reactions may be tolerated, and is worthy of further study.